CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
View All Press
